Biohacking News Podcast Por Inception Point Ai arte de portada

Biohacking News

Biohacking News

De: Inception Point Ai
Escúchala gratis

Biohacking News Tracker: Stay Ahead in the World of Biohacking

Welcome to "Biohacking News Tracker," your go-to podcast for the latest updates and breakthroughs in the world of biohacking. From cutting-edge technologies and genetic engineering to personalized health and wellness strategies, we cover it all. Each episode features expert interviews, in-depth analysis, and the most current news in biohacking and human optimization.

Join us as we explore the intersection of biology and technology, uncovering innovative ways to enhance human potential. Whether you're a biohacking enthusiast, a tech aficionado, or simply curious about the future of health, "Biohacking News Tracker" offers insightful and actionable information. Subscribe now and stay ahead in the rapidly evolving world of biohacking.

For more info https://www.quietperiodplease.com/Copyright 2025 Inception Point Ai Política y Gobierno
Episodios
  • Peptide Boom: FDA Loosening Rules, Market Hits $52.6B, What You Need to Know

    Peptide Boom: FDA Loosening Rules, Market Hits $52.6B, What You Need to Know
    Mar 19 2026
    In the past 48 hours, the biohacking industry shows momentum from regulatory shifts and product innovations, with RFK Jr. pushing to loosen FDA restrictions on nearly 20 peptides like ipamorelin, CJC-1295, BPC-157, and TB-500, potentially enabling U.S. compounding pharmacies to supply higher-quality versions and curb risky online imports.[1] This follows his recent Joe Rogan podcast comments, drawing support from physicians like Dr. Sue Decotiis for safer access under medical guidance, though experts caution on unproven safety and lack of human trials for many compounds.[1]

    Market data highlights growth: the global longevity ingredients sector, overlapping biohacking, hit $984.27 million in 2025 and projects $1,706.40 million by 2033 at 7.12% CAGR, with peptides and amino acids claiming 15% share; North America leads at 35%.[2] March 2026 saw spermidine supplements named U.S. award finalists for autophagy support and NAD+ injectable pens launch at wellness centers, signaling consumer shifts toward cellular repair tools.[2] Peptides overall reached a $52.6 billion market, with GLP-1 adoption at 1 in 8 U.S. adults.[8]

    New launches include U: The Mind Company's non-invasive brain device, an amplitude-modulated alternative to Neuralink, targeting focus and memory for biohackers; its Parkinson's trial is underway.[5] Weight-loss patches mimicking GLP-1 effects like Ozempic emerged as a 2026 trend, avoiding injections.[6]

    No major deals, disruptions, or price shifts reported in the last week, but leaders like Finnrick Analytics address supply impurities via testing.[1] Compared to early 2026's NAD+ gut health studies, current buzz amplifies peptides amid policy thaw, boosting influencer-driven demand without evident consumer pullback. Industry responds by prioritizing ethical sourcing and trials for credibility.[1][2] (298 words)

    For great deals today, check out https://amzn.to/44ci4hQ

    This content was created in partnership and with the help of Artificial Intelligence AI
    Más Menos
    2 m
  • Biohacking Conferences 2026: From Optimization Fatigue to Invisible Health Tech

    Biohacking Conferences 2026: From Optimization Fatigue to Invisible Health Tech
    Mar 18 2026
    The biohacking industry shows steady momentum in the past 48 hours, driven by major conference announcements rather than market disruptions or new deals. On March 17, 2026, Biohackers World revealed plans for its March 28-29 Los Angeles event, expecting over 1,500 attendees, 35 speakers, and 75 exhibitors focused on longevity science, AI health data, microbiome research, and testable wellness tech like light therapies.[1] Similarly, Dave Asprey announced the speaker lineup for his 14th annual BEYOND Biohacking Conference on May 27-29 in Austin, featuring experts like Jay Shetty, Dr. Gabrielle Lyon, and Patrick Kennedy, with 150 exhibitors offering PEMF therapy, stem cells, and hyperbaric oxygen.[2][3]

    No verified market movements, price changes, partnerships, regulatory shifts, or supply chain issues emerged in the last week; data remains sparse. The global wellness economy, tied to biohacking, hit 5.6 trillion dollars in 2023 and is projected to reach 8.5 trillion by 2027, reflecting sustained growth in wearables and metabolic tracking.[1]

    Consumer behavior hints at a backlash against over-optimization, with fatigue from constant self-surveillance pushing toward "invisible care" tech that embeds health monitoring without screens, per 2026 wellness trends.[5] New product launches include Reaper's Remedies "Die Slower" vitamins on March 17, satirizing longevity hype in a crowded field.[7]

    Leaders like Asprey respond by expanding beyond protocols to consciousness and nervous system regulation, emphasizing meaningful life over mere lifespan extension.[2][3] Mick Safron of Biohackers World highlights a shift from quick fixes to structured, data-driven everyday health.[1] Compared to prior reporting, this builds on rising preventive health interest without major pivots, positioning Austin and LA as hubs amid no evident disruptions. Overall, the sector buzzes with events amid subtle consumer pushback on hyper-tracking.(298 words)

    For great deals today, check out https://amzn.to/44ci4hQ

    This content was created in partnership and with the help of Artificial Intelligence AI
    Más Menos
    2 m
  • AI Biohacking Revolution: How Digital Biology and Luxury Wellness are Reshaping Health in 2026

    AI Biohacking Revolution: How Digital Biology and Luxury Wellness are Reshaping Health in 2026
    Mar 17 2026
    In the past 48 hours, the biohacking industry shows strong momentum driven by AI integration and luxury wellness demand. Nvidia CEO Jensen Huang highlighted digital biology as the next revolution, emphasizing AI for programmable biology and faster drug discovery, potentially slashing traditional 10 to 15 year timelines and 2 billion dollar costs.[1] This vision spotlights companies like Totaligent, which announced two binding Letters of Intent in February 2026 but gained fresh attention yesterday via market reports; one expands AI biologics via Aetherium acqui-hire, the other forms a joint venture with Japans GloMed Solutions, adding 10 million dollars annual revenue and 1 million in free cash flow from APAC clinics focused on peptides for metabolic and anti-aging therapies popular in biohacking.[1][2]

    New product buzz centers on the Ammortal Chamber, a 160,000 dollar home biohacking pod using red light, PEMF, and molecular hydrogen for inflammation reduction, ATP boost, and recovery; sessions start at 125 dollars, with elite athletes tracking gains via Oura Rings.[3] Upgrade Labs, an AI-driven fitness biohacking franchise, plans its Boulder, Colorado debut on March 27, expanding from California amid wellness booms.[4]

    Consumer shifts are evident: 60 percent of luxury buyers plan higher 2026 wellness spending in the 6.3 trillion dollar industry, fueling peptide injectables and cognitive programs like The Brain Song, reviewed March 15 for focus enhancement.[3][6] No major regulatory changes or disruptions reported, but supply chains strengthen via partnerships like Totaligents APAC push.

    Compared to prior weeks quieter news, this surge ties to Huangs comments, with leaders like Recursion Pharmaceuticals and Tempus AI leveraging Nvidia GPUs for data-heavy biohacks, reducing discovery from 42 to 18 months.[1] Biohacking evolves from niche to mainstream, blending AI precision with indulgent tech for longevity seekers. (298 words)

    For great deals today, check out https://amzn.to/44ci4hQ

    This content was created in partnership and with the help of Artificial Intelligence AI
    Más Menos
    2 m
Todavía no hay opiniones